Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Linkage of Periodontitis and Rheumatoid Arthritis: Current Evidence and Potential Biological Interactions.

de Molon RS, Rossa C Jr, Thurlings RM, Cirelli JA, Koenders MI.

Int J Mol Sci. 2019 Sep 13;20(18). pii: E4541. doi: 10.3390/ijms20184541. Review.

2.

Synovial Tissue Biopsy Collection by Rheumatologists: Ready for Clinical Implementation?

Smits M, van de Groes S, Thurlings RM.

Front Med (Lausanne). 2019 Jun 20;6:138. doi: 10.3389/fmed.2019.00138. eCollection 2019. Review.

3.

Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire.

Pollastro S, Klarenbeek PL, Doorenspleet ME, van Schaik BDC, Esveldt REE, Thurlings RM, Boumans MJH, Gerlag DM, Tak PP, Vos K, Baas F, van Kampen AHC, de Vries N.

Ann Rheum Dis. 2019 Oct;78(10):1339-1345. doi: 10.1136/annrheumdis-2018-214898. Epub 2019 Jun 19.

4.

The identification of CCL18 as biomarker of disease activity in localized scleroderma.

Mertens JS, de Jong EMGJ, van den Hoogen LL, Wienke J, Thurlings RM, Seyger MMB, Hoppenreijs EPAH, Wijngaarde CA, van Vlijmen-Willems IMJJ, van den Bogaard E, Giovannone B, van Wijk F, van Royen-Kerkhof A, Marut W, Radstake TRD.

J Autoimmun. 2019 Jul;101:86-93. doi: 10.1016/j.jaut.2019.04.008. Epub 2019 Apr 18.

PMID:
31006523
5.

Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis.

Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, Bruijnen STG, Safy M, Berger FH, Semmelink JF, van der Laken CJ, Gerlag DM, Thurlings RM, Tak PP.

Rheumatology (Oxford). 2019 Jun 1;58(6):1075-1085. doi: 10.1093/rheumatology/key428.

6.

Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity.

Arntz OJ, Pieters BCH, Thurlings RM, Wenink MH, van Lent PLEM, Koenders MI, van den Hoogen FHJ, van der Kraan PM, van de Loo FAJ.

Front Immunol. 2018 Oct 29;9:2388. doi: 10.3389/fimmu.2018.02388. eCollection 2018.

7.

A three-dimensional model to study human synovial pathology.

Broeren MGA, Waterborg CEJ, Wiegertjes R, Thurlings RM, Koenders MI, Van Lent PLEM, Van der Kraan PM, Van de Loo FAJ.

ALTEX. 2019;36(1):18-28. doi: 10.14573/altex.1804161. Epub 2018 Oct 9.

8.

Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial.

van den Hombergh WMT, Kersten BE, Knaapen-Hans HKA, Thurlings RM, van der Kraan PM, van den Hoogen FHJ, Fransen J, Vonk MC.

Trials. 2018 Aug 22;19(1):449. doi: 10.1186/s13063-018-2798-x.

9.

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis.

Tweehuysen L, den Broeder N, van Herwaarden N, Joosten LAB, van Lent PL, Vogl T, van den Hoogen FHJ, Thurlings RM, den Broeder AA.

RMD Open. 2018 Apr 9;4(1):e000654. doi: 10.1136/rmdopen-2018-000654. eCollection 2018.

10.

Regarding "Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea".

Mertens JS, de Jong EMGJ, Pandit A, Seyger MMB, Hoppenreijs EPAH, Thurlings RM, Vonk MC, Wienke J, van Wijk F, van Royen-Kerkhof A, Marut W, Radstake TRD.

J Invest Dermatol. 2018 May;138(5):1212-1215. doi: 10.1016/j.jid.2017.11.032. Epub 2017 Dec 12. No abstract available.

PMID:
29246801
11.

Long-term outcome of eosinophilic fasciitis: A cross-sectional evaluation of 35 patients.

Mertens JS, Thurlings RM, Kievit W, Seyger MMB, Radstake TRD, de Jong EMGJ.

J Am Acad Dermatol. 2017 Sep;77(3):512-517.e5. doi: 10.1016/j.jaad.2017.05.018. Epub 2017 Jul 19.

PMID:
28734566
12.

Morphea and Eosinophilic Fasciitis: An Update.

Mertens JS, Seyger MMB, Thurlings RM, Radstake TRDJ, de Jong EMGJ.

Am J Clin Dermatol. 2017 Aug;18(4):491-512. doi: 10.1007/s40257-017-0269-x. Review.

13.

Functional Tissue Analysis Reveals Successful Cryopreservation of Human Osteoarthritic Synovium.

Broeren MG, de Vries M, Bennink MB, van Lent PL, van der Kraan PM, Koenders MI, Thurlings RM, van de Loo FA.

PLoS One. 2016 Nov 21;11(11):e0167076. doi: 10.1371/journal.pone.0167076. eCollection 2016.

14.

Drug Survival and Predictors of Drug Survival for Methotrexate Treatment in a Retrospective Cohort of Adult Patients with Localized Scleroderma.

Mertens JS, van den Reek JM, Kievit W, van de Kerkhof PC, Thurlings RM, Radstake TR, Seyger MM, de Jong EM.

Acta Derm Venereol. 2016 Nov 2;96(7):943-947. doi: 10.2340/00015555-2411.

15.

A lethal case of the dapsone hypersensitivity syndrome involving the myocardium.

Hoogeveen RM, van der Bom T, de Boer HH, Thurlings RM, Wind BS, de Vries HJ, van Lent AU, Beuers U, van der Wal AC, Nellen FJ.

Neth J Med. 2016 Feb;74(2):89-92.

16.

In vivo imaging of enhanced leukocyte accumulation in atherosclerotic lesions in humans.

van der Valk FM, Kroon J, Potters WV, Thurlings RM, Bennink RJ, Verberne HJ, Nederveen AJ, Nieuwdorp M, Mulder WJ, Fayad ZA, van Buul JD, Stroes ES.

J Am Coll Cardiol. 2014 Sep 9;64(10):1019-29. doi: 10.1016/j.jacc.2014.06.1171.

17.

MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.

Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, Vogl T, Roth J, Tak PP, Holzinger D.

Ann Rheum Dis. 2015 Mar;74(3):499-505. doi: 10.1136/annrheumdis-2013-203923. Epub 2013 Dec 2.

PMID:
24297376
18.

Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue.

Mingozzi F, Chen Y, Edmonson SC, Zhou S, Thurlings RM, Tak PP, High KA, Vervoordeldonk MJ.

Gene Ther. 2013 Apr;20(4):417-24. doi: 10.1038/gt.2012.55. Epub 2012 Jul 12.

19.

Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis.

Boumans MJ, Thurlings RM, Yeo L, Scheel-Toellner D, Vos K, Gerlag DM, Tak PP.

Ann Rheum Dis. 2012 Jan;71(1):108-13. doi: 10.1136/annrheumdis-2011-200198. Epub 2011 Nov 8.

PMID:
22072013
20.

Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system.

Boumans MJ, Thurlings RM, Gerlag DM, Vos K, Tak PP.

Arthritis Rheum. 2011 Nov;63(11):3187-94. doi: 10.1002/art.30567. Review. No abstract available.

21.

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab.

Herenius MM, Thurlings RM, Wijbrandts CA, Bennink RJ, Dohmen SE, Voermans C, Wouters D, Izmailova ES, Gerlag DM, van Eck-Smit BL, Tak PP.

Ann Rheum Dis. 2011 Jun;70(6):1160-2. doi: 10.1136/ard.2010.141549. Epub 2011 Feb 22.

22.

Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression.

Gheorghe KR, Thurlings RM, Westman M, Boumans MJ, Malmström V, Trollmo C, Korotkova M, Jakobsson PJ, Tak PP.

PLoS One. 2011 Jan 27;6(1):e16378. doi: 10.1371/journal.pone.0016378.

23.

Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time?

van de Sande MG, Thurlings RM, Boumans MJ, Wijbrandts CA, Modesti MG, Gerlag DM, Tak PP.

Ann Rheum Dis. 2011 Apr;70(4):700-3. doi: 10.1136/ard.2010.139287. Epub 2010 Dec 20.

PMID:
21173012
24.

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.

Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, van Baarsen LG, Bos C, Kirou KA, Gerlag DM, Crow MK, Bijlsma JW, Verweij CL, Tak PP.

Arthritis Rheum. 2010 Dec;62(12):3607-14. doi: 10.1002/art.27702.

25.

Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity.

Kormelink TG, Tekstra J, Thurlings RM, Boumans MH, Vos K, Tak PP, Bijlsma JW, Lafeber FP, Redegeld FA, van Roon JA.

Ann Rheum Dis. 2010 Dec;69(12):2137-44. doi: 10.1136/ard.2009.126441. Epub 2010 Aug 2.

PMID:
20679475
26.

Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.

Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, van der Pouw Kraan TC, Verweij CL, Tak PP, Baeten DL.

Rheumatology (Oxford). 2010 Jan;49(1):156-66. doi: 10.1093/rheumatology/kep345. Epub 2009 Nov 23. Erratum in: Rheumatology (Oxford). 2014 Apr;53(4):770. van der Pouw, Tineke Kraan [corrected to van der Pouw Kraan, Tineke C T M].

PMID:
19933783
27.

Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease.

Thurlings RM, Wijbrandts CA, Bennink RJ, Dohmen SE, Voermans C, Wouters D, Izmailova ES, Gerlag DM, van Eck-Smit BL, Tak PP.

PLoS One. 2009 Nov 17;4(11):e7865. doi: 10.1371/journal.pone.0007865.

28.

The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.

Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP.

Arthritis Rheum. 2009 Nov;60(11):3217-24. doi: 10.1002/art.24913.

29.

Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers.

Bresnihan B, Pontifex E, Thurlings RM, Vinkenoog M, El-Gabalawy H, Fearon U, Fitzgerald O, Gerlag DM, Rooney T, van de Sande MG, Veale D, Vos K, Tak PP.

J Rheumatol. 2009 Aug;36(8):1800-2. doi: 10.3899/jrheum.090348.

PMID:
19671815
30.

A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.

van den Bemt BJ, Vos K, den Broeder AA, Blom M, Thurlings RM, Bartelds GM, Stapel SO, Barrera P, Tak PP, Nurmohamed MT, Wolbink GJ.

Ann Rheum Dis. 2009 Aug;68(8):1368-9. doi: 10.1136/ard.2008.095448. No abstract available.

PMID:
19605744
31.

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis.

Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, van Laar JM, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2010 Feb;69(2):409-12. doi: 10.1136/ard.2009.109041. Epub 2009 Jul 12.

PMID:
19596693
32.

Alterations of the synovial T cell repertoire in anti-citrullinated protein antibody-positive rheumatoid arthritis.

Cantaert T, Brouard S, Thurlings RM, Pallier A, Salinas GF, Braud C, Klarenbeek PL, de Vries N, Zhang Y, Soulillou JP, Tak PP, Baeten D.

Arthritis Rheum. 2009 Jul;60(7):1944-56. doi: 10.1002/art.24635.

33.

Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders.

Thurlings RM, Vos K, Gerlag DM, Tak PP.

Arthritis Rheum. 2008 Dec;58(12):3657-64. doi: 10.1002/art.24035.

34.

Biodistribution and radiation dosimetry of 99mTc-HMPAO-labeled monocytes in patients with rheumatoid arthritis.

Bennink RJ, Thurlings RM, van Hemert FJ, Voermans C, Dohmen SE, van Eck-Smit BL, Tak PP, Busemann-Sokole E.

J Nucl Med. 2008 Aug;49(8):1380-5. doi: 10.2967/jnumed.108.051755. Epub 2008 Jul 16.

35.

B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis.

Cantaert T, Kolln J, Timmer T, van der Pouw Kraan TC, Vandooren B, Thurlings RM, Cañete JD, Catrina AI, Out T, Verweij CL, Zhang Y, Tak PP, Baeten D.

J Immunol. 2008 Jul 1;181(1):785-94.

36.

Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype.

Thurlings RM, Wijbrandts CA, Mebius RE, Cantaert T, Dinant HJ, van der Pouw-Kraan TC, Verweij CL, Baeten D, Tak PP.

Arthritis Rheum. 2008 Jun;58(6):1582-9. doi: 10.1002/art.23505.

37.

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.

Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, Munafo A.

Arthritis Rheum. 2008 Jan;58(1):61-72. doi: 10.1002/art.23178.

38.

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.

Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP.

Ann Rheum Dis. 2008 Jul;67(7):917-25. Epub 2007 Oct 26.

39.

Mice lacking L1 have reduced CGRP fibre in-growth into spinal transection lesions.

Deumens R, Lübbers M, Jaken RJ, Meijs MF, Thurlings RM, Honig WM, Schachner M, Brook GA, Joosten EA.

Neurosci Lett. 2007 Jun 15;420(3):277-81. Epub 2007 May 10.

PMID:
17540505
40.

Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.

Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP.

Arthritis Rheum. 2007 Mar;56(3):772-8.

41.

[The humoral response in rheumatoid arthritis and the effect of B-cell depleting therapy].

Thurlings RM, Vos K, Gerlag DM, Tak PP.

Ned Tijdschr Geneeskd. 2006 Jul 29;150(30):1657-61. Review. Dutch.

PMID:
16922350

Supplemental Content

Loading ...
Support Center